Annual Secretarial Compliance Report for FY 2025-26
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma Ltd has filed its Annual Secretarial Compliance Report for FY 2025-26, certified by practicing company secretaries BK & Associates. The report confirms the company largely complied with SEBI regulations including LODR, PIT, and takeover regulations. However, three Related Party Transactions were entered without prior Audit Committee approval: (a) Rs.22.15 lakh with NATCO Lifesciences Philippines Inc. ratified in May 2025, (b) Rs.1.46 crore with Natcofarma Do Brasil Ltda. ratified in November 2025, and (c) $31,383 with Adcock Ingram Holdings Limited ratified in March 2026. All three were subsequently ratified by the Audit Committee and Board. No fines, penalties, or SEBI actions were imposed against the company.
The related party transaction deviations are minor compliance lapses that were retroactively corrected. No immediate shareholder impact, but investors should note the company's internal controls on RPT approvals may need strengthening.